CRG-150 / CoRegen - LARVOL DELTA

Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies (clinicaltrials.gov) - P1/2 | N=67 | Not yet recruiting | Sponsor: CoRegen, Inc.

First-in-human • New P1/2 trial • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • HER-2

CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types (Yahoo Finance) - "The IND clearance enables CoRegen to initiate a Phase 1/2a study that will evaluate CRG-150's safety and help determine optimal dosing. The Phase 1/2a first-in-human study will enroll patients diagnosed with metastatic triple negative breast cancer, metastatic HR+ HER2− breast cancer and metastatic prostate cancer populations, to assess safety, tolerability, cellular kinetics, and antitumor activity of CRG-150...CoRegen remains on track to initiate its Phase 1 trial this year and plans to expand into additional indications in the future, including glioblastoma and pancreatic cancer."

IND • New P1/2 trial • Glioblastoma • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Pancreatic Cancer • Prostate Cancer • Triple Negative Breast Cancer